~~<i id='B880A43BD4'><strike id='B880A43BD4'><tt id='B880A43BD4'><pre id='B880A43BD4'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：explore 2025-09-27 13:56:26 Page View：93

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Campaign finance charge dropped from case against Sam Bankman
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

Wikipedia

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Snowpack in the West is melting rapidly. Where will all that extra water go?

6:52Asthesnowpackmelts,waterflowsswiftlyinAlderCreek,onApril26,2023,inYosemiteNationalPark,Calif.Fra

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Adidas to release second batch of Yeezy sneakers after breakup with Ye

FILE-YeezyshoesmadebyAdidasaredisplayedatLacedUp,asneakerresalestore,inParamus,N.J.,onOct.25,2022.Ad